Richters A, Aben KKH, Kiemeney L (2020) The global burden of urinary bladder cancer: an update. World J Urol 38(8):1895–1904. https://doi.org/10.1007/s00345-019-02984-4

Article  PubMed  Google Scholar 

Berdik C (2017) Unlocking bladder cancer. Nature 551(7679):S34-s35. https://doi.org/10.1038/551S34a

Article  CAS  PubMed  Google Scholar 

Pardo JC, Ruiz de Porras V, Plaja A, Carrato C, Etxaniz O, Buisan O, Font A (2020) Moving towards personalized medicine in muscle-invasive bladder cancer: where are we now and where are we going? Int J Mol Sci. https://doi.org/10.3390/ijms21176271

Article  PubMed  PubMed Central  Google Scholar 

Schneider AK, Chevalier MF, Derré L (2019) The multifaceted immune regulation of bladder cancer. Nat Rev Urol 16(10):613–630. https://doi.org/10.1038/s41585-019-0226-y

Article  CAS  PubMed  Google Scholar 

Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D (2021) Advances in bladder cancer biology and therapy. Nat Rev Cancer 21(2):104–121. https://doi.org/10.1038/s41568-020-00313-1

Article  CAS  PubMed  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van’t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421. https://doi.org/10.1038/nature12477

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenis AT, Lec PM, Chamie K, Mshs MD (2020) Bladder cancer: a review. JAMA 324(19):1980–1991. https://doi.org/10.1001/jama.2020.17598

Article  CAS  PubMed  Google Scholar 

Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB (2021) Role of immunotherapy in bladder cancer. Cancer Treat Res Commun 26:100296. https://doi.org/10.1016/j.ctarc.2020.100296

Article  PubMed  Google Scholar 

Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651–668. https://doi.org/10.1038/s41577-020-0306-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perica K, Varela JC, Oelke M, Schneck J (2015) Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J 6(1):e0004. https://doi.org/10.5041/rmmj.10179

Article  PubMed  PubMed Central  Google Scholar 

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22(7):931–945. https://doi.org/10.1016/s1470-2045(21)00152-2

Article  CAS  PubMed  Google Scholar 

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 384(22):2102–2114. https://doi.org/10.1056/NEJMoa2034442

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou J, Wen X, Lu Z, Wu G, Yang G, Tang C, Qu G, Xu Y (2022) A novel T-cell proliferation-associated regulator signature pre-operatively predicted the prognostic of bladder cancer. Front Immunol 13:970949. https://doi.org/10.3389/fimmu.2022.970949

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu YT, Sun ZJ (2021) Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11(11):5365–5386. https://doi.org/10.7150/thno.58390

Article  CAS  PubMed  PubMed Central  Google Scholar 

Legut M, Gajic Z, Guarino M, Daniloski Z, Rahman JA, Xue X, Lu C, Lu L, Mimitou EP, Hao S, Davoli T, Diefenbach C, Smibert P, Sanjana NE (2022) A genome-scale screen for synthetic drivers of T cell proliferation. Nature 603(7902):728–735. https://doi.org/10.1038/s41586-022-04494-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550–1558. https://doi.org/10.1038/s41591-018-0136-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Audisio A, Buttigliero C, Delcuratolo MD, Parlagreco E, Audisio M, Ungaro A, Di Stefano RF, Di Prima L, Turco F, Tucci M (2022) New perspectives in the medical treatment of non-muscle-invasive bladder cancer: immune checkpoint inhibitors and beyond. Cells. https://doi.org/10.3390/cells11030357

Article  PubMed  PubMed Central  Google Scholar 

Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clini Oncol Off J Am Soc Clin Oncol 32(34):3801–3809. https://doi.org/10.1200/jco.2014.57.5548

Article  Google Scholar 

Gakis G (2020) Management of muscle-invasive bladder cancer in the 2020s: challenges and perspectives. Eur Urol Focus 6(4):632–638. https://doi.org/10.1016/j.euf.2020.01.007

Article  PubMed  Google Scholar 

Ward Grados DF, Ahmadi H, Griffith TS, Warlick CA (2022) Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol Invest 51(8):2226–2251. https://doi.org/10.1080/08820139.2022.2118606

Article  CAS  PubMed  Google Scholar 

Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C (2022) Immunotherapy: reshape the tumor immune microenvironment. Front Immunol 13:844142. https://doi.org/10.3389/fimmu.2022.844142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):1–11. https://doi.org/10.1038/s12276-018-0191-1

Article  CAS  PubMed  Google Scholar 

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. https://doi.org/10.1126/science.1129139

Article  CAS  PubMed  Google Scholar 

Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery 18(3):197–218. https://doi.org/10.1038/s41573-018-0007-y

Article  CAS  PubMed  Google Scholar 

Arneth B (2019) Tumor microenvironment. Medicina (Kaunas). https://doi.org/10.3390/medicina56010015

Article  PubMed  Google Scholar 

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782–795. https://doi.org/10.1016/j.immuni.2013.10.003

Article